Linezolid is an oxazolidinone with antimicrobial activity against gram-positive bacteria indicated for the treatment of infections by multiresistant Staphylococcus aureus and coagulase-negative staphylococci, as well as penicillin-resistant Streptococcus pneumoniae and vancomycin-resistant enterococci. Resistance has developed sporadically during therapy in both enterococci and S. aureus . Staphylococci colonised health care workers transfer staphylococci to patients they take care of and are a risk for hospital acquired infections. This study was carried out to primarily determine the prevalence of linezolid resistance in nasal staphylococcal isolates from health care workers  Study sample included 197 nasal staphylococci isolated from health care workers of our tertiary care hospital. Resistance to methicillin was detected by disc diffusion method of Kirby Bauer using 30 µg cefoxitin discs and Linezolid resistance was detected by disc diffusion method of Kirby Bauer using 30 µg linezolid discs according to CLSI 2011 guidelines. Out of 197 staphylococci isolated, 38(18.44%) were methicillin sensitive S.aureus, 45(21.84%) were methicillin resistant S.aureus. 63(30.58%) were methicillin sensitive coagulase negative staphylococci and 61(29.61%) were methicillin resistant coagulase negative staphylococci. In the present study, all (100%) staphylococcal isolates were sensitive to linezolid. Although reports of linezolid resistance are still uncommon and resistance rates are still low from reports of many studies, emerging linezolid resistance in staphylococcal isolates is a matter of great concern. Resistance surveillance studies among patients and screening of health care workers for linezolid resistant staphylococcal carriage should be conducted regularly to monitor resistance to linezolid. Paucity of newer antibiotics demands judicious use of linezolid to preserve its clinical utility.